The flow of money to startups trying to leverage CRISPR/Cas-9 technology for clinical purposes apparently is limitless. 

Intellia Therapeutics this week said that it raised $70 million in a Series B funding round that drew some heavyweight investors, including OrbiMed HealthCare Fund Management, Fidelity Management and Research, Janus Capital Management, and others. Founding investors Atlas Venture and Novartis also participated in the round. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a commentary at eLife, Brandeis University's Eve Marder calls on researchers to value and pursue truth.

Researchers have developed a way to quickly edit white blood cells, according to the New York Times.

In Science this week: rice gene enables plants to grow quickly in times of flooding, and more.

Scientific American reports that environmental DNA sampling can detect invasive brown marmorated stinkbugs before they've fully invaded a farm.